Over the past 12 months, 0 insiders at CymaBay Therapeutics, Inc. filed 0 open-market SEC Form 4 transactions on CBAY: 0 purchases worth $0 and 0 sales worth $0. Insiders have been mixed over this period. The most recent filing was on .
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 12, 24 | Janet DorlingDirector | SELL | 6.0K | $31.97 | $192K |
| Jan 19, 24 | Charles McWherterPresident of R&D | SELL | 8.3K | $23.68 | $197K |
| Jan 16, 24 | Daniel MenoldVice President, Finance | SELL | 10.0K | $23.58 | $236K |
| Jan 16, 24 | Paul T QuinlanGeneral Counsel | SELL | 5.0K | $23.58 | $118K |
| Jan 10, 24 | Janet DorlingDirector | SELL | 6.0K | $23.86 | $143K |
| Dec 18, 23 | Charles McWherterPresident of R&D | SELL | 6.5K | $21.49 | $140K |
| Dec 15, 23 | Daniel MenoldVice President, Finance | SELL | 11.5K | $21.99 | $253K |
| Dec 15, 23 | Paul T QuinlanGeneral Counsel | SELL | 5.0K | $21.98 | $110K |
| Dec 11, 23 | Janet DorlingDirector | SELL | 6.0K | $20.07 | $120K |
| Dec 11, 23 | Sujal ShahChief Executive Officer | SELL | 64.0K | $20.81 | $1.3M |
| Nov 17, 23 | Charles McWherterPresident of R&D | SELL | 11.3K | $18.28 | $207K |
| Nov 15, 23 | Daniel MenoldVice President, Finance | SELL | 0 | $17.38 | $0 |
| Nov 15, 23 | Paul T QuinlanGeneral Counsel | SELL | 5.0K | $17.38 | $87K |
| Nov 13, 23 | Sujal ShahChief Executive Officer | SELL | 44.0K | $15.89 | $699K |
| Nov 10, 23 | Janet DorlingDirector | SELL | 7.0K | $15.24 | $107K |
| Oct 18, 23 | Charles McWherterPresident of R&D | SELL | 21.7K | $14.07 | $306K |
| Oct 16, 23 | Daniel MenoldVice President, Finance | SELL | 0 | $13.76 | $0 |
| Oct 16, 23 | Paul T QuinlanGeneral Counsel | SELL | 5.0K | $13.76 | $69K |
| Oct 9, 23 | Sujal ShahChief Executive Officer | SELL | 64.9K | $14.20 | $921K |
| Sep 29, 23 | Kurt Von EmsterDirector | SELL | 15.9K | $15.68 | $250K |
| Sep 18, 23 | Charles McWherterPresident of R&D | SELL | 21.7K | $16.22 | $353K |
| Sep 15, 23 | Daniel MenoldVice President, Finance | SELL | 0 | $16.87 | $0 |
| Sep 15, 23 | Paul T QuinlanGeneral Counsel | SELL | 24.0K | $16.87 | $405K |
| Aug 18, 23 | Charles McWherterPresident of R&D | SELL | 21.7K | $11.47 | $249K |
| Aug 15, 23 | Daniel MenoldVice President, Finance | SELL | 0 | $12.13 | $0 |
| Aug 15, 23 | Paul T QuinlanGeneral Counsel | SELL | 5.0K | $11.91 | $60K |
| Aug 9, 23 | Daniel MenoldVice President, Finance | SELL | 20.9K | $12.35 | $259K |
| Jul 18, 23 | Charles McWherterPresident of R&D | SELL | 21.7K | $11.43 | $249K |
| Jul 14, 23 | Paul T QuinlanGeneral Counsel | SELL | 5.0K | $11.81 | $59K |
| Jun 30, 23 | Paul T QuinlanGeneral Counsel | SELL | 5.0K | $10.05 | $50K |
| Jun 20, 23 | Charles McWherterPresident of R&D | SELL | 21.7K | $8.16 | $177K |
| May 18, 23 | Charles McWherterPresident of R&D | SELL | 21.7K | $9.08 | $197K |
| May 15, 23 | Paul T QuinlanGeneral Counsel | SELL | 5.0K | $10.37 | $52K |
| Apr 17, 23 | Dennis D KimChief Medical Officer | SELL | 112.2K | $9.54 | $1.1M |
| Apr 13, 23 | Dennis D KimChief Medical Officer | SELL | 7.8K | $8.98 | $70K |
| Mar 28, 23 | Dennis D KimChief Medical Officer | SELL | 100 | $8.99 | $899 |
| Jun 6, 22 | Sujal ShahChief Executive Officer | BUY | 51.3K | $1.95 | $100K |
| Jan 19, 22 | Dennis D KimChief Medical Officer | BUY | 20.0K | $3.04 | $61K |
Over the past 12 months, insiders at CymaBay Therapeutics, Inc. filed 0 open-market purchases worth $0 and 0 sales worth $0 on CBAY, which makes them mixed over the period. The most recent Form 4 was filed on .
The largest recent open-market CBAY insider purchase in our data was $100K by Sujal Shah, Chief Executive Officer, filed on Jun 6, 22.
0 different insiders at CymaBay Therapeutics, Inc. filed open-market SEC Form 4 transactions on CBAY over the last 12 months.
InsiderTape plots every CBAY insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every CymaBay Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →